Introduction
============

Fluconazole-resistance has emerged among *Candida* species since the beginning of the fluconazole era as a result of the selective pressure caused by prophylaxis and therapeutic management \[[@B1]\]. Emergence and development of antifungal drug resistance in *Candida* species isolates have serious concerns in terms of therapeutic failures mainly related to echinocandins and azoles resistance \[[@B2]\]*. Candida auris* has become an emerging serious public health threat \[[@B3]\] since the recognition of the first case from Japan in 2009 \[[@B4]\].

During the last ten years, the number of reported cases has drastically increased, including six outbreaks during 2013 and 2017 \[[@B5]-[@B10]\]. *Candida auris* infection has recently been reported from all continents. However, sporadic cases of *C. auris* have been reported from Austria, Belgium, Malaysia, the Netherlands, Norway, Russia, Switzerland, United Arab Emirates, and Iran \[[@B11]-[@B12]\]. Challenges in laboratory detection, unique predisposition to cause nosocomial outbreaks, and multidrug-resistant phenotypes of *C. auris* are the rule \[[@B13]\]. As a consequence of its ability to overcome antifungal therapy, *C. auris* continuously increases its ecological niche and resistance to environmental conditions. Accordingly, the multidrug-resistant phenotypes of *C. auris* may be associated with hospital-acquired infections \[[@B14]-[@B15]\].

Although most *C. auris*isolates are resistant to fluconazole and elevated the minimum inhibitory concentrations (MICs) of amphotericin B and echinocandins have been reported, echinocandins have been the most active drugs up to now \[[@B16]-[@B18]\]. Therefore, to overcome the growing challenge of antifungal resistance, a valuable alternative option would be the use of drug combinations \[[@B19]\].

Successful combination therapy for the treatment of fungal infectious diseases can achieve broader antifungal coverage and potentially reduce acquired resistance. Nonsteroidal anti-inflammatory drugs (NSAIDs), i.e., ibuprofen, diclofenac, and aspirin, show antifungal activity against *Candida*species alone or in combination with antifungal agents \[[@B20]-[@B25]\]. Antifungal activity of NSAIDs is related to the inhibition of the cyclooxygenase enzyme (COX) that leads to decreased prostaglandin levels. It seems that the suppression of oxylipins, oxygenated fatty acid metabolites derived from arachidonic acid, by NSAIDs can reduce the hyphal formation of *C. albicans* \[[@B20], [@B25]\].

Although the potential antifungal activities of NSAIDs against *Candida* species, such as the changes in prostaglandin production, reduction of extracellular polysaccharide, decrease in hyphal and biofilm formations, which may provide evidence for a combination strategy against pathogenic yeast, are known \[[@B20]-[@B25]\], no study has investigated the combination of NSAIDs and fluconazole against multi drug resistant *C. auris*. Therefore, the current study evaluated the *in vitro* combination of NSAIDs (i.e., ibuprofen, diclofenac, and aspirin) with fluconazole against fluconazole-resistant *C. auris* in comparison to other fluconazole-resistant *Candida* species.

Materials and Methods
=====================

***Strains and identification***

A set of 16 clinically important *Candida* species comprising, *C. auris*(n=6), *C. albicans* (n=2), *C. glabrata* (n=2), *C. parapsilosis* (n=2), *C. tropicalis* (n=2), and *C. krusei* (n=2) originating from patients with candidiasis, was used. None *Candida auris* strains were isolated from pediatric patients suffering from hematological malignancies under chemotherapy and/or radiotherapy. All tested isolates have been previously identified by both DNA sequencing of internal transcribed spacer (ITS-rDNA) regions and MALDI-TOF mass spectrometer assay (MALDI Biotyper OC version 3.1, Bruker Daltonics, Bremen, Germany) \[[@B26]\]. Isolates were sub-cultured on Sabouraud Dextrose Agar (SDA, Difco) at 30 °C to ensure purity and viability.

***In vitro antifungal susceptibility testing***

Fluconazole MICs were determined according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) ([Table 1](#T1){ref-type="table"}) \[[@B27], [@B28]\]. *Candida albicans*(ATCC 64124) was used as a reference strain for azole resistance with mutation in the azole target *Erg11* \[[@B29]\].

###### 

Minimum inhibitory concentrations of fluconazole and nonsteroidal anti-inflammatory drugs (i.e., ibuprofen, diclofenac, and aspirin) alone and in combination against *Candida auris* and other fluconazole-resistant *Candida*species

  **No.**   **Strains**         **Country of origin**   **MIC values (µg/ml)**                                                                
  --------- ------------------- ----------------------- ------------------------ ------ ------ ------ ------------------- ------------------- -------------------
  1         *C. auris*          India                   128                      4096   2048   2048   128/2048 (1.5/I)    128/2048 (2/I)      64/512 (0.75/I)
  2         *C. auris*          India                   256                      2048   8192   2048   128/1024 (1/I)      64/2048 (0.5/I)     256/1024 (1.5/I)
  3         *C. auris*          India                   256                      2048   2048   4096   64/2048 (1.25/I)    128/1024 (1/I)      256/1024 (1.25/I)
  4         *C. auris*          India                   256                      4096   8192   2048   128/2048 (1/I)      256/2048 (1.25/I)   128/1024 (1/I)
  5         *C. auris*          India                   256                      4096   2048   2048   128/1024 (0.75/I)   64/1024 (0.75/I)    128/512 (0.75/I)
  6         *C. auris*          Iran                    32                       2048   4096   1024   32/2048 (2/I)       16/2048 (1/I)       32/1024 (2/I)
  7         *C. albicans*       Iran                    256                      512    1024   1024   32/64 (0.25/S)      32/256 (0.375/S)    16/256 (0.3125/S)
  8         *C. albicans*       Iran                    256                      1024   1024   1024   16/256 (0.3125/S)   128/1024 (1.5/I)    8/128 (0.1562/S)
  9         *C. tropicalis*     Iran                    64                       256    2048   2048   16/32 (0.375/S)     64/1024 (1.5/I)     8/512 (0.375/S)
  10        *C. tropicalis*     Iran                    16                       256    512    1024   64/256 (5/A)        64/512 (5/A)        16/512 (1.5/I)
  11        *C. parapsilosis*   Iran                    128                      2048   2048   2048   64/1024 (1/I)       128/512 (1.25/I)    128/2048 (2/I)
  12        *C. parapsilosis*   Iran                    64                       1024   1024   2048   64/512 (1.5/I)      64/1024 (2/I)       32/2048 (1.5/I)
  13        *C. glabrata*       Iran                    16                       4096   2048   2048   16/1024 (1.25/I)    16/2048 (2/I)       16/2048 (2/I)
  14        *C. glabrata*       Iran                    256                      2048   4096   2048   32/256 (0.25/S)     256/2048 (1.5/I)    128/1024 (1/I)
  15        *C. krusei*         Iran                    128                      1024   2048   1024   16/64 (0.1875/S)    128/2048 (2/I)      128/2048 (3/I)
  16        *C. krusei*         Iran                    64                       1024   2048   1024   32/512 (1/I)        64/2048 (2/I)       64/1024 (2/I)

MIC: Minimum inhibitory concentrations, FICI: Fractional inhibitory concentration index, FLZ: fluconazole, IBR: ibuprofen, DIC: diclofenac, ASA: aspirin, I: Indifference, S: Synergism, A: Antagonism

***In vitro combination testing***

A checkerboard microdilution assay based on the CLSI reference technique was performed in 96-well microtiter plates to evaluate the *in vitro* interactions between NSAIDs (i.e., ibuprofen, diclofenac, and aspirin) and fluconazole against azole-resistant *Candida* species \[[@B30]\]. The drugs were dissolved in 100% dimethyl sulfoxide (DMSO), and the concentrations were within the range of 0.5 to 128 µg/ml for fluconazole (FLZ; Pfizer, Groton, CT, USA), 32 to 2048 µg/ml for ibuprofen (IBR, Sigma), and aspirin (ASA, Sigma) and 64 to 4096 µg/ml for diclofenac (DIC, Sigma). Briefly, 50 µl of each concentration of fluconazole was dispensed into the columns of 1 to 10, and 50 µl of NSAIDs (IBR or DIC or ASA) was added to the rows of A to G of 96-well microplates. The H row and column 11 contained fluconazole and NSAIDs alone, respectively. In addition, column 12 was used as the drug-free growth control. The inoculum was prepared using fresh colonies, and their density was adjusted to 1-3 × 10^3^ CFU/ml at 530 nm wavelength to a percentage transmission within the range of 75-77% according to CLSI M27-S4 guide \[[@B26]\].

For each drug combination plate, 100 µl of inoculum was added to all the wells, and the plates were incubated at 35 °C for 24 h. The test was performed in duplicate on two separate days. The MICs were visually determined as the lowest concentration of drug that reduced growth (≥50% inhibition) in comparison to growth controls. For the determination of drug interactions, fractional inhibitory concentration index (FICI) was calculated as MIC drug A in combination/MIC drug A alone plus MIC drug B in combination/MIC drug B alone and interpreted as synergism (FICI≤0.5), indifference (0.5\<FICI≤4), and antagonism (FICI\>4) \[[@B30]\].

Results
=======

[Table 1](#T1){ref-type="table"} summarizes the results of the MICs of fluconazole and NSAIDs (i.e., ibuprofen, diclofenac, and aspirin) alone and in combination. The MIC ranges of the individual tested NSAIDs against *C. auris*isolates were 256-4096, 512-8192, and 1024-4096 µg/ml for ibuprofen, diclofenac, and aspirin, respectively. However, the MIC range of fluconazole against *C. auris*was 32-256 µg/ml. Based on MIC values, all tested strains were fully resistant to fluconazole, except for one strain of *C. glabrata* that was susceptible dose-dependent, and the MIC range of fluconazole against other non-*albicans* species was 16-256 µg/ml.

Checkerboard microdilution assays of *C. auris* showed that when fluconazole was combined with NSAIDs, the MIC ranges of fluconazole-ibuprofen and fluconazole-diclofenac decreased from 32-256 to 32-128 and 16-256 µg/ml, respectively. In addition, it remained the same for fluconazole-aspirin ([Table 1](#T1){ref-type="table"}) suggestive of the indifferent combinations between fluconazole with ibuprofen, diclofenac, or aspirin (FICI\>0.5 to ≤4).

The most common obtained result of the checkerboard assay in this study was indifferent (i.e., 62.5%, 87.5%, and 81.25% for fluconazole-ibuprofen, fluconazole-diclofenac, and fluconazole-aspirin, respectively). However, the *in vitro* combination of fluconazole with ibuprofen resulted in a synergistic effect for 5 strains, including *C. albicans* (n=2), *C. tropicalis* (n=1), *C. glabrata* (n=1), and *C. krusei* (n=1), by decreasing the MIC of fluconazole by 2-3 log~2~ dilutions.

Synergistic interactions between fluconazole and aspirin were recorded for three strains and observed in only one instance synergism when fluconazole was combined with diclofenac. None of the analyzed data sets had FICI higher than 4, indicating that no antagonism was observed except for one *C. tropicalis* strain in which the combinations of fluconazole with ibuprofen and fluconazole with diclofenac showed an antagonistic effect.

Discussion
==========

*Candida auris*is one of the top-ten most serious fungal pathogens to date \[[@B31]\]. Despite the application of antifungal therapy, management is a big challenge because*C. auris*is a persistent colonizer and difficult to eradicate from the hospital environment \[[@B32], [@B33]\]. Moreover, the ability to form biofilms, adherence to catheter material, and resistance to the major antifungal drugs may have contributed to its persistence and nosocomial transmission \[[@B7], [@B10]\]. Pan-resistance of *C. auris* has been reported with the high MICs of fluconazole (90%), echinocandins (2%), amphotericin B (8%), and voriconazole (2.3%) \[[@B16]\].

In addition, Khan et al. reported that 100% (56/56) of the *C. auris* isolates were fluconazole-resistant 73% (41/56) and 23 % (13/56) of the isolates exhibited cross-resistance to voriconazole and amphotericin B, respectively. Furthermore, 20% (11/56) of the isolates were simultaneously resistant to fluconazole, voriconazole, as well as amphotericin B, and one isolate demonstrated resistance to caspofungin and micafungin \[[@B34]\].

Our previous experience on the interaction of caspofungin with voriconazole and micafungin with fluconazole against multidrug-resistant *C. auris* revealed indifferent activities against all strains (FICI, 0.62 to 2). Nonetheless, the synergistic effects of micafungin with voriconazole were observed (FICI, 0.15 to 0.5) and no antagonism was identified for any combinations \[[@B35]\].

In a study carried out by Eldesouky et al., it was reported that sulfamethoxazole had the highest synergistic activity with fluconazole against both *C. albicans* and *C. auris* \[[@B36]\]*.* In this regard, the fluconazole MICs of *C. auris* were reduced by 8 log~2~dilutions resulting in an FICI of 0.156 \[[@B37]\].

In our previous study, geldanamycin interacted synergistically with both fluconazole and itraconazole against *C. albicans*, *C. glabrata*, and *C. parapsilosis*. However these combinations were indifferent against *C. auris* \[[@B38]\]. Significant inhibitory effects of NSAIDs on the growth of *Candida* species, *Trichosporon asahii,* and *Cryptococcus* species have been previously reported \[[@B20]\].

Furthermore, there have been reports of the *in vitro* synergistic effect of fluconazole with ibuprofen, sodium salicylate, or propylparaben against *C. albicans* \[[@B21], [@B23]\]. In a study carried out by Scott et al. a synergistic interaction was observed between NSAIDs and fluconazole against azole-resistant *C.* *albicans.* Moreover, NSAIDs were able to revert the azole resistance of *C. albicans*at clinically relevant concentrations, *in vitro* \[[@B23]\]. In this regard, the results of the aforementioned study are in line with the findings of the present study.

In the present study, the combination of fluconazole with ibuprofen resulted in a synergistic effect against *C. albicans* (n=2), *C. tropicalis* (n=1), *C. glabrata* (n=1), and *C. krusei* (n=1). Similar to the findings of the present study, Pina-Vaz et al. demonstrated that the combination of ibuprofen with fluconazole had synergic activity in four fluconazole-resistant strains, including *C. glabrata* (n=2), C. *albicans*(n=1), and *C. krusei* (n=1). Furthermore, they recommended the practicability of using ibuprofen alone or in combination with azoles in the treatment of candidiasis, particularly when topically applied \[[@B21]\].

Conclusion
==========

In summary, the results of the present study showed that the interaction of NSAIDs and fluconazole had a synergistic activity against azole-resistant *C. albicans* and *C. tropicalis*, but indifferent effects were observed for both resistant *C. auris* and *C. krusei*. Although the interaction of NSAIDs and fluconazole was not synergistic against resistant *C. auris* isolates, the combination with newer azole agents would be another option. However, the significance of these *in vitro* findings remains elusive and requires consideration.
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